LYST and neoplasm: Specifically, lipid–polymer hybrid nanoparticles (LPHNs) functionalized with CHS-specific surface ligands (e.g., anti-CD44v6) could be engineered for OC delivery, facilitating tumor-specific uptake and stromal penetration.